for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Axcella Health Inc

AXLA.OQ

Latest Trade

3.40USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

3.03

 - 

6.84

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
3.40
Open
--
Volume
--
3M AVG Volume
6.87
Today's High
--
Today's Low
--
52 Week High
6.84
52 Week Low
3.03
Shares Out (MIL)
38.18
Market Cap (MIL)
129.81
Forward P/E
-1.89
Dividend (Yield %)
--

Next Event

Q3 2021 Axcella Health Inc Earnings Release

Latest Developments

More

Axcella Reports Q1 Loss Per Share $0.40

Axcella Reports Fourth Quarter And Full Year 2020 Financial Results And Provides Business Update

Axcella Announces Ind Clearance For Axa1665, Program Updates And 2021 Milestones

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Axcella Health Inc

Axcella Health Inc. is a biotechnology company. The Company focuses on research and development of multifactorial interventions to support health and address dysregulated metabolism across a spectrum of consumers. It designs and develops endogenous metabolic modulators. Its AXA Development Platform produces a pipeline of AXA candidates with programs in liver, muscle and blood. The Company’s wholly owned pipeline comprises five programs focused on the metabolic functions of the liver, muscle and blood. It offers AXA1665 for use in treating Hepatic Encephalopathy; AXA1125 and AXA1957 to treat non-alcoholic fatty liver disease; AXA2678 for use in treating immobilization-induced acute muscle atrophy; and AXA4010 to target multiple biological pathways.

Industry

Biotechnology & Drugs

Contact Info

840 Memorial Dr

CAMBRIDGE, MA

02139-3789

United States

+1.617.8680949

http://www.axcellahealth.com/

Executive Leadership

David R. Epstein

Chairman of the Board

William Hinshaw

President, Chief Executive Officer, Director

Laurent Chardonnet

Chief Financial Officer, Senior Vice President

Alison D. Schecter

President - Research and Development

Shreeram Aradhye

Executive Vice President, Chief Medical Officer, Director

Key Stats

2.00 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2019

-3.550

2020

-1.780

2021(E)

-1.787
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
2.67
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-60.24
Return on Equity (TTM)
-57.03

Latest News

Latest News

BRIEF-Axcella Announces Patent Issuances Covering AXA1665

* AXCELLA ANNOUNCES PATENT ISSUANCES COVERING AXA1665 Source text for Eikon: Further company coverage:

BRIEF-Axcella Health Says Entered Into Sales Agreement With SVB Leerink Relating To Shares Of Common Stock Offered By Prospectus

* AXCELLA HEALTH - ENTERED INTO SALES AGREEMENT WITH SVB LEERINK LLC RELATING TO SHARES OF COMMON STOCK OFFERED BY PROSPECTUS

BRIEF-Axcella Health Files For $125 Million Mixed Shelf

* AXCELLA HEALTH FILES FOR $125 MILLION MIXED SHELF - SEC FILING Source text: (https://bit.ly/37brM4P) Further company coverage:

BRIEF-Axcella Announces Pricing Of Public Offering Of Common Stock

* AXCELLA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Axcella Health Inc Files For Offering Of Up To 11.0 Mln Shares Of Common Stock

* AXCELLA HEALTH INC FILES FOR OFFERING OF UP TO 11.0 MILLION SHARES OF COMMON STOCK - SEC FILING Source: (https://bit.ly/3fFrU0l) Further company coverage:

BRIEF-Axcella Reports Q1 Loss Per Share Of $0.65

* AXCELLA REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Axcella Announces Positive Top-Line Data From AXA1125-003 Clinical Study Showing Multifactorial Activity In Adult Subjects With NAFLD

* AXCELLA ANNOUNCES POSITIVE TOP-LINE DATA FROM AXA1125-003 CLINICAL STUDY SHOWING MULTIFACTORIAL ACTIVITY IN ADULT SUBJECTS WITH NAFLD

BRIEF-Axcella Receives Fourth Patent Covering Emm Compositions

* AXCELLA RECEIVES FOURTH PATENT COVERING EMM COMPOSITIONS Source text for Eikon: Further company coverage:

BRIEF-Axcella Health Q4 Loss Per Share $0.68

* AXCELLA REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Axcella Announces Oral Presentation At 2020 International Conference On Frailty And Sarcopenia Research

* AXCELLA ANNOUNCES ORAL PRESENTATION AT 2020 INTERNATIONAL CONFERENCE ON FRAILTY AND SARCOPENIA RESEARCH Source text for Eikon: Further company coverage:

BRIEF-Axcella Completes Enrollment Of Subjects In Axa1665-002 Study

* AXCELLA COMPLETES ENROLLMENT OF SUBJECTS IN AXA1665-002 STUDY

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up